Associated Papers
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Katayama R et al.
Nature Communications, 2019
31399568 (PubMed )
Supplement: 41467_2019_11496_MOESM1_ESM.pdf
Select a paper to view details